|Bid||76.17 x 900|
|Ask||76.40 x 3000|
|Day's range||75.34 - 77.15|
|52-week range||53.22 - 78.47|
|Beta (5Y monthly)||0.48|
|PE ratio (TTM)||26.99|
|Earnings date||27 Jul 2022|
|Forward dividend & yield||2.16 (2.80%)|
|Ex-dividend date||31 Mar 2022|
|1y target est||79.40|
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
PRINCETON, N.J., May 19, 2022--Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.